Anti-CXCR1 compositions and methods
The present invention provides methods of treating cancer by administering an IL8-CXCR1 pathway inhibitor (e.g., an anti-CXCR1 antibody or Repertaxin) alone or in combination with an additional chemotherapeutic agent such that non-tumorigenic and tumorigenic cancer cells in a subject are killed. The present invention also provides compositions and methods for detecting the presence of and isolating solid tumor stem cells in a patient (e.g., based on the presence of CXCR1 or FBXO21).
1. A method of treating a human subject diagnosed with ER-negative breast cancer, comprising:
(a) administering a pharmaceutical composition containing an effective concentration of Compound 1 to the human subject in need of said treatment, wherein Compound 1 is:
and
(b) administering an effective concentration of paclitaxel to the subject in need of said treatment.
2. The method of claim 1 in which Compound 1 is administered at a dose between 3 and 60 mg per kg.
3. A method of treating a human subject diagnosed with metastatic ER-negative breast cancer, comprising:
(a) administering a pharmaceutical composition containing an effective concentration of Compound 1 to the human subject in need of said treatment, wherein Compound 1 is:
and
(b) administering an effective concentration of paclitaxel to the human subject in need thereof.
4. The method of claim 3 , in which Compound 1 is administered at a dose between 3 and 60 mg per kg.
5. The method of claim 1 , wherein Compound 1 is administered concurrently with paclitaxel.
6. The method of claim 1 , wherein Compound 1 is administered at a time prior to the administration of paclitaxel.
7. The method of claim 1 , wherein Compound 1 is administered at a time subsequent to the administration of paclitaxel.
8. The method of claim 3 , wherein Compound 1 is administered concurrently with paclitaxel.
9. The method of claim 3 , wherein Compound 1 is administered at a time prior to the administration of paclitaxel.
10. The method of claim 3 , wherein Compound 1 is administered at a time subsequent to the administration of paclitaxel.
11. The method of claim 3 , wherein the method results in a reduction of metastasis.
12. The method of claim 3 , wherein Compound 1 is administered orally.